Science Explorer Back to mapMap
Discussion
Institution · Deciphera Pharmaceuticals (United States)

Most cited papers from Deciphera Pharmaceuticals (United States)

Deciphera Pharmaceuticals (United States)

What are the most cited papers from Deciphera Pharmaceuticals (United States)?

The most cited paper from Deciphera Pharmaceuticals (United States) is "Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial" (Jean‐Yves Blay, César Serrano, Michael Charles Heinrich et al., 2020), with 430 citations. Next come "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers" (312) and "Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants" (285).

Showing 50 of 60 papers. Every paper with more than 11 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial Jean‐Yves Blay, César Serrano, Michael Charles Heinrich et al. · The Lancet Oncology Open access 5 Jun 2020 430
2 Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers Sheng-Bin Peng et al. · Cancer Cell Open access Sep 2015 312
3 Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants Bryan D. Smith et al. · Cancer Cell Open access May 2019 285
4 Composite grading algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Ethan Basch, Claus C. Becker, Lauren J. Rogak et al. · Clinical Trials Open access Dec 2020 256
5 Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036 Wayne W. Chan et al. · Cancer Cell Open access Apr 2011 213
6 The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors Allison S. Harney, George S. Karagiannis, Jeanine Pignatelli et al. · Molecular Cancer Therapeutics Open access 24 Aug 2017 174
7 Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells Leslie A. Parsels, Meredith Ann Morgan, Daria M. Tanska et al. · Molecular Cancer Therapeutics Open access 2009 146
8 Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial Sebastian Bauer, Robin L. Jones, Jean‐Yves Blay et al. · Journal of Clinical Oncology Open access 10 Aug 2022 121
9 The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile Christopher A. Eide, Lauren T. Adrian, Jeffrey Tyner et al. · Cancer Research Open access 19 Apr 2011 119
10 Three novel patient‐derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors Sara Redaelli, Luca Mologni, Roberta Rostagno et al. · American Journal of Hematology 26 Sep 2012 113
11 AXL regulates mesothelioma proliferation and invasiveness W-B Ou, Joseph M. Corson, Darren Flynn et al. · Oncogene 6 Dec 2010 94
12 Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib Filip Jankú, Albiruni R. Abdul Razak, Ping Chi et al. · Journal of Clinical Oncology Open access 17 Aug 2020 91
13 Multipolymer Solution-Phase Reactions: Application to the Mitsunobu Reaction Andrew M. Harned, Helen Song He, Patrick H. Toy et al. · Journal of the American Chemical Society 13 Dec 2004 91
14 A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer Ryan Joseph Sullivan et al. · Molecular Cancer Therapeutics 23 Oct 2019 89
15 Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2 Bryan D. Smith et al. · Molecular Cancer Therapeutics 18 Aug 2015 81
16 Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Hans A. J. Gelderblom et al. · The Lancet Open access Jun 2024 79
17 Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages Bryan D. Smith, Michael D. Kaufman, Scott Wise et al. · Molecular Cancer Therapeutics Open access 25 Aug 2021 74
18 Targeted Inhibition of Multiple Receptor Tyrosine Kinases in Mesothelioma Wen‐Bin Ou, Christopher G. Hubert, Jonathan Alfred Fletcher et al. · Neoplasia Open access 2011 72
19 Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models Yuji Piao, Soon Young Park, Verlene K. Henry et al. · Neuro-Oncology Open access 9 Mar 2016 69
20 NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors Romel Somwar, Nicolle E. Hofmann, Bryan D. Smith et al. · Communications Biology Open access 16 Dec 2020 62
21 Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial Michael Charles Heinrich et al. · Nature Medicine Open access 5 Jan 2024 61
22 Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment Youngjoo Kwon, Barbara D. Smith, Yan Zhou et al. · Oncogene Open access 23 Dec 2013 60
23 Intrigue: Phase III Study of Ripretinib Versus Sunitinib in Advanced Gastrointestinal Stromal Tumor After Imatinib John J. Nemunaitis, Sebastian Bauer, Jean‐Yves Blay et al. · Future Oncology Open access 22 Nov 2019 56
24 Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1—Clinical) Fabien Ricard et al. · Journal of Nuclear Medicine Open access 14 Jul 2022 55
25 Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ Lina Ding et al. · Nature Communications Open access 13 Sep 2019 54
26 Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia Jörge E. Cortes, Moshe Talpaz, Hedy Patricia Smith et al. · Haematologica Open access 7 Dec 2016 53
27 Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study Sebastian Bauer, Michael Charles Heinrich, Suzanne George et al. · Clinical Cancer Research Open access 9 Sep 2021 45
28 Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer Atish Dipankar Choudhury et al. · Cancer Immunology Research Open access 29 Mar 2024 44
29 Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT) Timothy M. Caldwell, Yu Mi Ahn, Stacie L. Bulfer et al. · Bioorganic & Medicinal Chemistry Letters Open access 10 Aug 2022 44
30 Oligomeric Benzylsulfonium Salts: Facile Benzylation via High-Load ROMP Reagents Mianji Zhang, Daniel Lee Flynn, Paul R. Hanson · The Journal of Organic Chemistry Apr 2007 42
31 Ring-Opening Metathesis Phase-Trafficking (ROMpt) Synthesis: Multistep Synthesis on Soluble ROM Supports Andrew M. Harned, Shubhasish Mukherjee, Daniel Lee Flynn et al. · Organic Letters 10 Dec 2002 40
32 Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation Yun Bai, Geethani Bandara, Eunice Ching Chan et al. · Leukemia Open access 31 Jul 2012 40
33 The hnRNP RALY regulates transcription and cell proliferation by modulating the expression of specific factors including the proliferation marker E2F1 Nicola Cornella, Toma Tebaldi, Lisa Gasperini et al. · Journal of Biological Chemistry Open access 3 Oct 2017 37
34 Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma Pavlina Chuntova, Akane Yamamichi, Tiffany Chen et al. · Journal for ImmunoTherapy of Cancer Open access May 2022 35
35 Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region Yu Mi Ahn, Michael Andrew Clare, Carol L. Ensinger et al. · Bioorganic & Medicinal Chemistry Letters Open access 4 Aug 2010 35
36 Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study John Raymond Zalcberg, Michael Charles Heinrich, Suzanne George et al. · The Oncologist Open access 27 Jul 2021 34
37 High-Load, Oligomeric Dichlorotriazine: A Versatile ROMP-Derived Reagent and Scavenger Alan Rolfe, Donald A. Probst, Kelly A. Volp et al. · The Journal of Organic Chemistry Open access 21 Oct 2008 34
38 Non-clinical Pharmacology of YTX-7739: a Clinical Stage Stearoyl-CoA Desaturase Inhibitor Being Developed for Parkinson’s Disease Daniel F. Tardiff, Matthew C. Lucas, Iwona E. Wrona et al. · Molecular Neurobiology Open access 20 Jan 2022 32
39 Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour Suzanne George, Ping Chi, Michael Charles Heinrich et al. · European Journal of Cancer Open access 12 Aug 2021 31
40 CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib Hans A. J. Gelderblom et al. · Clinical Cancer Research Open access 12 Jul 2024 30
41 Switch Pocket Inhibitors of the ABL Tyrosine Kinase: Distinct Kinome Inhibition Profiles and in Vivo Efficacy in Mouse Models of CML and B-Lymphoblastic Leukemia Induced by BCR-ABL T315I Richard A. Van Etten, Wayne W. Chan, Virginia M. Zaleskas et al. · Blood 16 Nov 2008 27
42 Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis Anu Gupta, Jarnail Singh, Alfonso García‐Valverde et al. · Molecular Cancer Therapeutics 4 May 2021 24
43 Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine Josephine Amalia Taverna, Chia‐Nung Hung, Madison H. Williams et al. · Lung Cancer Open access 14 Mar 2024 23
44 Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens Suzanne George, Michael Charles Heinrich, Ping Chi et al. · Annals of Oncology Open access Oct 2018 22
45 Inhibition of ULK1/2 and KRASG12C controls tumor growth in preclinical models of lung cancer Phaedra C. Ghazi, Kayla T. O’Toole, Sanjana Srinivas Boggaram et al. · eLife Open access 30 Aug 2024 21
46 System X−c Antiporter Inhibitors: Azo-Linked Amino-Naphthyl-Sulfonate Analogues of Sulfasalazine M. Nehser, John G. Dark, D. Schweitzer et al. · Neurochemical Research Open access 21 Nov 2019 20
47 The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations Suzanne George, Jean‐Yves Blay, Ping Chi et al. · Future Oncology Open access 26 Aug 2024 19
48 Opportunities and Challenges in Implementation of Multiparameter Single Cell Analysis Platforms for Clinical Translation Susan M. Keating, D. Lansing Taylor, Anne L. Plant et al. · Clinical and Translational Science Open access 2 Mar 2018 19
49 1540P Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study Margaret von Mehren, Michael Charles Heinrich, Suzanne George et al. · Annals of Oncology Open access Sep 2021 18
50 INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753) Margaret von Mehren, César Serrano, Sebastian Bauer et al. · Annals of Oncology Open access Oct 2019 18

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.